Home › Companies › IMMUNOVANT INC. › 2024-2025

IMMUNOVANT INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and IMMUNOVANT INC.’s Form 8-K, filed 2024-08-13 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
228Asset managers
1,420Fund votes
2024-08-12Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IMMUNOVANT INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by IMMUNOVANT INC.

These tallies are IMMUNOVANT INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-08-13 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IMMUNOVANT INC. — official shareholder meeting results, meeting held 2024-08-12
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Peter Salzmann, M.D., M.B.A.	99,849,994	--	--	31,897,811	6,513,760	Majority: yes
Elect Director: George Migausky	98,023,809	--	--	33,723,996	6,513,760	Majority: yes
Elect Director: Douglas Hughes	97,129,496	--	--	34,618,309	6,513,760	Majority: yes
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fi	138,241,628	16,740	3,197	--	--	Majority: yes

Source: IMMUNOVANT INC., Form 8-K, filed with the SEC on 2024-08-13 — read the filing on EDGAR.

How asset managers voted at the IMMUNOVANT INC. 2024-2025 meeting

Each item below shows how the 228 asset managers that disclosed a IMMUNOVANT INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of IMMUNOVANT INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

93% fund support · no official result

FOR 93%

The 212 asset managers below cast 93% of the shares they voted on this item FOR (62,406,543 for, 4,685,919 against).

FOR: 62,406,543 (93.0%)AGAINST: 4,685,919 (7.0%)ABSTAIN: 2,595 (0.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at IMMUNOVANT INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	17,630,418	0	For
Vanguard	6,505,456	0	For
State Street	5,274,614	1,049	For
T. Rowe Price	5,032,990	0	For
BlackRock	3,573,925	11,397	For
VIKING GLOBAL INVESTORS LP	2,317,402	0	For
Deep Track Capital, LP	1,981,490	0	For
ARMISTICE CAPITAL, LLC	1,686,825	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,330,501	0	For
Nuveen	1,185,121	0	For
Rock Springs Capital Management LP	1,167,694	0	For
PICTET ASSET MANAGEMENT SA	1,133,782	0	For
Capital Group	0	976,237	Against
Capital Research Global Investors	0	976,237	Against
FRANKLIN ADVISERS INC	960,229	0	For
Charles Schwab	897,005	0	For
TIAA	861,221	0	For
Invesco	0	821,368	Against
Paradigm Biocapital Advisors LP	804,771	0	For
Aberdeen	801,444	0	For
Commodore Capital LP	750,990	0	For
Logos Global Management LP	720,501	0	For
Victory Capital	640,790	0	For
FRED ALGER MANAGEMENT, LLC	0	612,865	Against
ALGER FUNDS	0	496,198	Against

Showing the 25 largest of 212 asset managers. See all 212 in the interactive database.

2. To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas Hughes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%

FOR: 97,129,496WITHHELD: 34,618,309

IMMUNOVANT INC.’s own tally for this item (“Elect Director: Douglas Hughes”): 97,129,496 for, 34,618,309 withheld, per its Form 8-K filed 2024-08-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 146,195,673 outstanding shares: 66% for, 24% withheld (90% of the company cast a for/withheld vote).

The 75 asset managers below cast 100% of the shares they voted on this item FOR (8,395,082 for, 0 against).

FOR 32%ABSTAIN 68%

FOR: 8,395,082 (31.8%)ABSTAIN: 18,016,836 (68.2%)

Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at IMMUNOVANT INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	0	7,338,989	Abstain
Vanguard	6,304,664	0	For
State Street	2,202	2,117,777	Abstain
T. Rowe Price	0	2,114,983	Abstain
BlackRock	0	1,768,466	Abstain
Capital Group	976,237	0	For
TIAA	0	861,221	Abstain
ALGER FUNDS	0	496,198	Abstain
Charles Schwab	448,502	0	For
Aberdeen	0	400,722	Abstain
Invesco	0	361,064	Abstain
FRANKLIN STRATEGIC SERIES	325,213	0	For
Principal	0	268,304	Abstain
Victory Capital	0	237,974	Abstain
Jackson National	99,699	88,499	For
Dimensional	0	164,319	Abstain
Direxion Shares ETF Trust	0	163,407	Abstain
Equitable	0	140,918	Abstain
Nuveen	0	132,676	Abstain
Delaware/Macquarie	0	122,100	Abstain
Bridge Builder Trust	0	118,494	Abstain
Russell Investments	109,695	0	For
QUANTITATIVE MASTER SERIES LLC	0	102,304	Abstain
FINANCIAL INVESTORS TRUST	0	88,339	Abstain
Lincoln Financial	0	86,236	Abstain

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

3. To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: George Migausky

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%

FOR: 98,023,809WITHHELD: 33,723,996

IMMUNOVANT INC.’s own tally for this item (“Elect Director: George Migausky”): 98,023,809 for, 33,723,996 withheld, per its Form 8-K filed 2024-08-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 146,195,673 outstanding shares: 67% for, 23% withheld (90% of the company cast a for/withheld vote).

The 75 asset managers below cast 100% of the shares they voted on this item FOR (8,878,064 for, 0 against).

FOR 34%ABSTAIN 66%

FOR: 8,878,064 (33.6%)ABSTAIN: 17,533,854 (66.4%)

Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at IMMUNOVANT INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	0	7,338,989	Abstain
Vanguard	6,304,664	0	For
State Street	2,202	2,117,777	Abstain
T. Rowe Price	0	2,114,983	Abstain
BlackRock	0	1,768,466	Abstain
Capital Group	976,237	0	For
TIAA	0	861,221	Abstain
ALGER FUNDS	0	496,198	Abstain
Charles Schwab	448,502	0	For
Aberdeen	0	400,722	Abstain
Invesco	361,064	0	For
FRANKLIN STRATEGIC SERIES	325,213	0	For
Principal	147	268,157	Abstain
Victory Capital	0	237,974	Abstain
Jackson National	99,699	88,499	For
Dimensional	0	164,319	Abstain
Direxion Shares ETF Trust	0	163,407	Abstain
Equitable	0	140,918	Abstain
Nuveen	0	132,676	Abstain
Delaware/Macquarie	0	122,100	Abstain
Bridge Builder Trust	0	118,494	Abstain
Russell Investments	109,695	0	For
QUANTITATIVE MASTER SERIES LLC	0	102,304	Abstain
FINANCIAL INVESTORS TRUST	0	88,339	Abstain
Lincoln Financial	0	86,236	Abstain

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

4. To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Peter Salzmann, M.D., M.B.A.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD 24%

FOR: 99,849,994WITHHELD: 31,897,811

IMMUNOVANT INC.’s own tally for this item (“Elect Director: Peter Salzmann, M.D., M.B.A.”): 99,849,994 for, 31,897,811 withheld, per its Form 8-K filed 2024-08-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 146,195,673 outstanding shares: 68% for, 22% withheld (90% of the company cast a for/withheld vote).

The 75 asset managers below cast 100% of the shares they voted on this item FOR (7,568,056 for, 0 against).

FOR 29%ABSTAIN 71%

FOR: 7,568,056 (28.7%)ABSTAIN: 18,843,862 (71.3%)

Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at IMMUNOVANT INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	24,862	7,314,127	Abstain
Vanguard	0	6,304,664	Abstain
State Street	2,117,232	2,747	For
T. Rowe Price	1,109,309	1,005,674	For
BlackRock	1,768,466	0	For
Capital Group	976,237	0	For
TIAA	0	861,221	Abstain
ALGER FUNDS	0	496,198	Abstain
Charles Schwab	448,502	0	For
Aberdeen	0	400,722	Abstain
Invesco	0	361,064	Abstain
FRANKLIN STRATEGIC SERIES	325,213	0	For
Principal	147	268,157	Abstain
Victory Capital	0	237,974	Abstain
Jackson National	99,699	88,499	For
Dimensional	0	164,319	Abstain
Direxion Shares ETF Trust	0	163,407	Abstain
Equitable	85,268	55,650	For
Nuveen	0	132,676	Abstain
Delaware/Macquarie	0	122,100	Abstain
Bridge Builder Trust	10,052	108,442	Abstain
Russell Investments	109,695	0	For
QUANTITATIVE MASTER SERIES LLC	102,304	0	For
FINANCIAL INVESTORS TRUST	0	88,339	Abstain
Lincoln Financial	52,235	34,001	For

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

5. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 138,241,628AGAINST: 16,740

IMMUNOVANT INC.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent regi”): 138,241,628 for, 16,740 against, per its Form 8-K filed 2024-08-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 146,195,673 outstanding shares: 95% for, 0.1% against (95% of the company cast a for/against vote).

The 75 asset managers below cast 99.9% of the shares they voted on this item FOR (26,409,094 for, 229 against).

FOR 99.9%

FOR: 26,409,094 (100.0%)AGAINST: 229 (0.0%)ABSTAIN: 2,595 (0.0%)

Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independe” at IMMUNOVANT INC., 2024-2025
Asset manager	For	Vote
Fidelity	7,338,989	For
Vanguard	6,304,664	For
State Street	2,119,979	For
T. Rowe Price	2,114,983	For
BlackRock	1,768,466	For
Capital Group	976,237	For
TIAA	861,221	For
ALGER FUNDS	496,198	For
Charles Schwab	448,502	For
Aberdeen	400,722	For
Invesco	361,064	For
FRANKLIN STRATEGIC SERIES	325,213	For
Principal	268,304	For
Victory Capital	237,974	For
Jackson National	188,198	For
Dimensional	164,319	For
Direxion Shares ETF Trust	163,407	For
Equitable	140,918	For
Nuveen	132,676	For
Delaware/Macquarie	122,100	For
Bridge Builder Trust	118,494	For
Russell Investments	109,695	For
QUANTITATIVE MASTER SERIES LLC	102,304	For
FINANCIAL INVESTORS TRUST	88,339	For
Lincoln Financial	86,236	For

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

99.9% fund support · no official result

FOR 93%

The 9 asset managers below cast 99.9% of the shares they voted on this item FOR (633,034 for, 632 against).

FOR: 633,034 (93.2%)AGAINST: 632 (0.1%)ABSTAIN: 45,500 (6.7%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at IMMUNOVANT INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	274,634	0	0	For
JPMorgan	186,602	0	0	For
Eversept Partners, LP	82,013	0	0	For
EFG Asset Management (North America) Corp.	58,070	0	0	For
Erste Asset Management GmbH	0	0	45,500	Abstain
ALGERT GLOBAL LLC	31,674	0	0	For
Desjardins Global Asset Management Inc.	0	632	0	Against
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	41	0	0	For
Metzler Asset Management GmbH	0	0	0	--

7. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (825,000 for, 0 against).

FOR: 825,000 (100.0%)

Largest asset managers voting on “14A Executive Compensation” at IMMUNOVANT INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Boxer Capital Management, LLC	825,000	0	0	0	For
Tyro Capital Management LLC	0	0	0	0	--

Largest IMMUNOVANT INC. shareholders voting in 2024-2025

Ranked by the number of IMMUNOVANT INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 146,195,673 shares outstanding at the time of that meeting.

Top IMMUNOVANT INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Fidelity	12.06%
2	Vanguard	4.45%
3	State Street	3.61%
4	T. Rowe Price	3.44%
5	BlackRock	2.45%
6	VIKING GLOBAL INVESTORS LP	1.59%
7	Deep Track Capital, LP	1.36%
8	ARMISTICE CAPITAL, LLC	1.15%
9	GEODE CAPITAL MANAGEMENT, LLC	0.91%
10	Nuveen	0.81%

Reported IMMUNOVANT INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

IMMUNOVANT INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Roivant Sciences Ltd.	77.52%	13D
FMR (Fidelity)	11.79%	13F
FMR LLC	11.68%	DEF14A
Entities affiliated with Deep Track Capital, LP	6.50%	DEF14A
Vanguard Group	4.74%	13F
BlackRock	3.67%	13F
Peter Salzmann, M.D.	2.49%	DEF14A
State Street	2.11%	13F
Frank M. Torti, M.D.	1.17%	DEF14A
Geode Capital	1.14%	13F

Percentages above are of 146,195,673 shares outstanding, as reported by IMMUNOVANT INC. on its Form 10-Q dated 2024-06-30 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IMMUNOVANT INC.’s 10-Q dated 2024-06-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At IMMUNOVANT INC.'s shareholder meeting held 2024-08-12, in the 2024-2025 proxy season, 228 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,420 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. IMMUNOVANT INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — the reporting funds cast 93% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

IMMUNOVANT INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.